Name: Development and Application of Rapamycin-regulated Tyrosine Phosphatases (Video) | JoVE Journal
Uploaded: 2024-09-06T14:10:00.000+00:00
Duration: 6 min 56 s
Description: Learn to develop rapamycin-regulated tyrosine phosphatases for temporal control of SHIP-2 activity in HEK-293T cells. This method reveals specific effects on cell spreading and migration.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors acknowledge Dr. Jordan Fauser for her contribution to the development of RapR-Shp2 and associated protocols. The work was supported by a 5R35GM145318 award from NIGMS, an R33CA258012 award from NCI, and a P01HL151327 award from NHLBI.

Temporal Regulation of Phosphatase Activity with the Rapamycin-Regulated System

<ol><li>Amin, A. R. M. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((SHP-2+tyrosine+phosphatase+inhibits+p73-dependent+apoptosis+and+expression+of+a+subset+of+p53+target+genes+induced+by+EGCG%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+U+S+A%22%5BJournal%5D)">SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG.</a> Proc Natl Acad Sci U S A. 104 (13), 5419-5424 (2007).</li>
<li>Niogret, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Shp-2+is+critical+for+ERK+and+metabolic+engagement+downstream+of+IL-15+receptor+in+NK+cells%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells.</a> Nat Commun. 10, 1-14 (2019).</li>
<li>Wang, Y. -C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Helicobacter+pylori+infection+activates+Src+homology-2+domain-containing+phosphatase+2+to+suppress+IFN-%CE%B3+signaling%5BTitle%5D)+AND+%22J+Immunol%22%5BJournal%5D)">Helicobacter pylori infection activates Src homology-2 domain-containing phosphatase 2 to suppress IFN-γ signaling.</a> J Immunol. 193 (8), 4149-4158 (2014).</li>
<li>Yu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+tyrosine+phosphatase+SHP2+promotes+proliferation+and+oxaliplatin+resistance+of+colon+cancer+cells+through+AKT+and+ERK%5BTitle%5D)+AND+%22Biochem+Biophys+Res+Commun%22%5BJournal%5D)">The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.</a> Biochem Biophys Res Commun. 563, 1-7 (2021).</li>
<li>Lauriol, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Developmental+SHP2+dysfunction+underlies+cardiac+hypertrophy+in+Noonan+syndrome+with+multiple+lentigines%5BTitle%5D)+AND+%22J+Clin+Invest%22%5BJournal%5D)">Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.</a> J Clin Invest. 126 (8), 2989-3005 (2016).</li>
<li>Tartaglia, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mutations+in+PTPN11%2C+encoding+the+protein+tyrosine+phosphatase+SHP-2%2C+cause+Noonan+syndrome%5BTitle%5D)+AND+%22Nat+Genet%22%5BJournal%5D)">Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.</a> Nat Genet. 29, 465-468 (2001).</li>
<li>Xu, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Overexpression+of+Shp2+tyrosine+phosphatase+is+implicated+in+leukemogenesis+in+adult+human+leukemia%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.</a> Blood. 106 (9), 3142-3149 (2005).</li>
<li>Mustelin, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protein+tyrosine+phosphatases%5BTitle%5D)+AND+%22Front+Biosci%22%5BJournal%5D)">Protein tyrosine phosphatases.</a> Front Biosci. 7 (4), d85-d142 (2002).</li>
<li>Stanford, S. M., Bottini, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeting+tyrosine+phosphatases%3A+time+to+end+the+stigma%5BTitle%5D)+AND+%22Trends+Pharmacol+Sci%22%5BJournal%5D)">Targeting tyrosine phosphatases: time to end the stigma.</a> Trends Pharmacol Sci. 38 (6), 524-540 (2017).</li>
<li>Guo, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeting+phosphatases%3A+From+molecule+design+to+clinical+trials%5BTitle%5D)+AND+%22Eur+J+Med+Chem%22%5BJournal%5D)">Targeting phosphatases: From molecule design to clinical trials.</a> Eur J Med Chem. 264, 116031(2024).</li>
<li>Weiser, D. C., Shenolikar, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+protein+phosphatase+inhibitors%5BTitle%5D)+AND+%22Curr+Protoc+Mol+Biol%22%5BJournal%5D)">Use of protein phosphatase inhibitors.</a> Curr Protoc Mol Biol. 62, 1-18 (2003).</li>
<li>Fauser, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dissecting+protein+tyrosine+phosphatase+signaling+by+engineered+chemogenetic+control+of+its+activity%5BTitle%5D)+AND+%22J+Cell+Biol%22%5BJournal%5D)">Dissecting protein tyrosine phosphatase signaling by engineered chemogenetic control of its activity.</a> J Cell Biol. 221 (8), e202111066(2022).</li>
<li>Karginov, A. V., Hahn, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Allosteric+activation+of+kinases%3A+design+and+application+of+RapR+kinases%5BTitle%5D)+AND+%22Curr+Protoc+Cell+Biol%22%5BJournal%5D)">Allosteric activation of kinases: design and application of RapR kinases.</a> Curr Protoc Cell Biol. , Chapter 14, Unit 14.13 (2011).</li>
<li>Karginov, A. V., Ding, F., Kota, P., Dokholyan, N. V., Hahn, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineered+allosteric+activation+of+kinases+in+living+cells%5BTitle%5D)+AND+%22Nat+Biotechnol%22%5BJournal%5D)">Engineered allosteric activation of kinases in living cells.</a> Nat Biotechnol. 28, 743-747 (2010).</li>
<li>Dagliyan, O., Dokholyan, N. V., Hahn, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineering+proteins+for+allosteric+control+by+light+or+ligands%5BTitle%5D)+AND+%22Nat+Protoc%22%5BJournal%5D)">Engineering proteins for allosteric control by light or ligands.</a> Nat Protoc. 14, 1863-1883 (2019).</li>
<li>Wang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeting+the+SHP2+phosphatase+promotes+vascular+damage+and+inhibition+of+tumor+growth%5BTitle%5D)+AND+%22EMBO+Mol+Med%22%5BJournal%5D)">Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.</a> EMBO Mol Med. 13, e14089(2021).</li>
<li>Wang, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((SHP2+regulates+the+development+of+intestinal+epithelium+by+modifying+OSTERIX%2B+crypt+stem+cell+self-renewal+and+proliferation%5BTitle%5D)+AND+%22FASEB+J%22%5BJournal%5D)">SHP2 regulates the development of intestinal epithelium by modifying OSTERIX+ crypt stem cell self-renewal and proliferation.</a> FASEB J. 35, e21106(2021).</li>
<li>Zhang, E. E., Chapeau, E., Hagihara, K., Feng, G. -S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neuronal+Shp2+tyrosine+phosphatase+controls+energy+balance+and+metabolism%5BTitle%5D)+AND+%22Proc+Natl+Acad+Sci+U+S+A%22%5BJournal%5D)">Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism.</a> Proc Natl Acad Sci U S A. 101 (45), 16064-16069 (2004).</li>
<li>Song, Y., Zhao, M., Zhang, H., Yu, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Double-edged+roles+of+protein+tyrosine+phosphatase+SHP2+in+cancer+and+its+inhibitors+in+clinical+trials%5BTitle%5D)+AND+%22Pharmacol+Ther%22%5BJournal%5D)">Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.</a> Pharmacol Ther. 230, 107966(2022).</li>
<li>Hartman, Z. R., Schaller, M. D., Agazie, Y. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+tyrosine+phosphatase+SHP2+regulates+focal+adhesion+kinase+to+promote+EGF-induced+lamellipodia+persistence+and+cell+migration%5BTitle%5D)+AND+%22Mol+Cancer+Res%22%5BJournal%5D)">The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.</a> Mol Cancer Res. 11 (6), 651-664 (2013).</li>
<li>Yu, D. H., Qu, C. K., Henegariu, O., Lu, X., Feng, G. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protein-tyrosine+phosphatase+Shp-2+regulates+cell+spreading%2C+migration%2C+and+focal+adhesion%5BTitle%5D)+AND+%22J+Biol+Chem%22%5BJournal%5D)">Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.</a> J Biol Chem. 273 (33), 21125-21131 (1998).</li>
<li>Kramer, M. F., Coen, D. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enzymatic+amplification+of+DNA+by+PCR%3A+standard+procedures+and+optimization%5BTitle%5D)+AND+%22Curr+Protoc+Cell+Biol%22%5BJournal%5D)">Enzymatic amplification of DNA by PCR: standard procedures and optimization.</a> Curr Protoc Cell Biol. 10, 1-14 (2001).</li>
<li>Sandhu, G. S., Precup, J. W., Kline, B. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Rapid+one-step+characterization+of+recombinant+vectors+by+direct+analysis+of+transformed+Escherichia+coli+colonies%5BTitle%5D)+AND+%22Biotechniques%22%5BJournal%5D)">Rapid one-step characterization of recombinant vectors by direct analysis of transformed Escherichia coli colonies.</a> Biotechniques. 7, 689-690 (1989).</li>
<li>Tsygankov, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CellGeo%3A+A+computational+platform+for+the+analysis+of+shape+changes+in+cells+with+complex+geometries%5BTitle%5D)+AND+%22J+Cell+Biol%22%5BJournal%5D)">CellGeo: A computational platform for the analysis of shape changes in cells with complex geometries.</a> J Cell Biol. 204 (3), 443-460 (2014).</li>
<li>Schneider, C. A., Rasband, W. S., Eliceiri, K. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((NIH+Image+to+ImageJ%3A+25+years+of+image+analysis%5BTitle%5D)+AND+%22Nat+Methods%22%5BJournal%5D)">NIH Image to ImageJ: 25 years of image analysis.</a> Nat Methods. 9, 671-675 (2012).</li>
<li>Ray, A. -M., Klomp, J. E., Collins, K. B., Karginov, A. V. Dissecting kinase effector signaling using the RapRTAP methodology. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aRay%2C+A-M+%22Kinase+Signaling+Networks%22">Kinase Signaling Networks</a>. Tan, A. -C., Huang, P. H. , Springer. New York, NY. 21-33 (2017).</li>
<li>Mercan, F., Bennett, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Analysis+of+protein+tyrosine+phosphatases+and+substrates%5BTitle%5D)+AND+%22Curr+Protoc+Mol+Biol%22%5BJournal%5D)">Analysis of protein tyrosine phosphatases and substrates.</a> Curr Protoc Mol Biol. 18, Unit 18.16 (2010).</li>
<li>Karginov, A. V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Light+regulation+of+protein+dimerization+and+kinase+activity+in+living+cells+using+photocaged+rapamycin+and+engineered+FKBP%5BTitle%5D)+AND+%22J+Am+Chem+Soc%22%5BJournal%5D)">Light regulation of protein dimerization and kinase activity in living cells using photocaged rapamycin and engineered FKBP.</a> J Am Chem Soc. 133 (3), 420-423 (2011).</li>
<li>Karginov, A. V., Hahn, K. M., Deiters, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optochemical+activation+of+kinase+function+in+live+cells%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Optochemical activation of kinase function in live cells.</a> Methods Mol Biol. 1148, 31-43 (2014).</li>
</ol>

The authors have no conflicts of interest to disclose.

This protocol provides detailed steps for the development, characterization, and application of chemogenetically controlled phosphatases. The RapR-Shp2 tool relies on a rapamycin-regulated switch inserted in the Shp2 catalytic domain. The strength of this tool is the specificity and tight temporal control of phosphatase activity. The tool is applicable to other phosphatases and, in combination with previously described RapR-TAP technology, allows for the reconstruction of individual downstream signaling pathways26. Unique capabilities of the RapR approach allowed researchers to identify transient events induced by activation of Shp2 and dissect specific downstream signaling pathways regulating individual morphodynamic processes. 
Several critical factors influence the design of a RapR phosphatase. A well-resolved crystal structure of the catalytic domain of the phosphatase of interest is very helpful in guiding the selection of the insertion site for iFKBP. However, due to high structural similarity among tyrosine phosphatases, alignment of the amino acid sequences of the catalytic domains could provide sufficient information for the identification of the insertion site as illustrated by the alignment of Shp2 to PTP1B and PTPPest (Figure 2). For RapR-Shp2, Val406, located in the site coupled to the critical catalytic WPD loop through a &#946;-strand, was chosen as the most optimal insertion site. The same insertion site may result in successful regulation of other PTPases, as was demonstrated for PTP1B and PTP-PEST12 (Figure 2A).
If the phosphatase of interest is a multidomain protein, structural information about the organization of the domains will help prevent interfering with other functions of the PTPase. Another factor influencing the design of optimal RapR-PTPase is how many amino acids should be replaced by inserted iFKBP. Larger and more flexible insertion loops in the PTPase may require additional shortening to ensure tight regulation of catalytic activity by iFKBP. Similarly, the length and the composition of the linkers connecting iFKBP to the PTPase will affect the efficiency of regulation. Short linkers composed of a single Gly residue will provide tighter regulation but may reduce the maximum activity of the enzyme if they introduce persistent structural distortion even when iFKBP is bound to rapamycin and FRB. Medium length Gly-Ser-Gly linkers provide more flexibility but may not be rigid enough for some PTPases. Long linkers composed of Gly-Ser-Gly-Gly-Pro-Gly will help prevent the formation of unintended secondary structures that may influence PTPase regulation. RapR-Shp2 was tested with all three types of linkers; a Gly-Ser-Gly linker was found to be the most optimal. 
A critical aspect determining the successful development of RapR tools is the establishment of a robust phosphatase assay and the presence of appropriate controls. Comparison of RapR-phosphatase activity to the activity of dominant-negative and constitutively active versions of the POI provides an assessment of the leakiness of the RapR-construct and the extent of activation. Furthermore, the lack of dephosphorylation by the constitutively active phosphatase or reduced phosphorylation by the dominant negative mutant will indicate improper reaction conditions. 
For the phosphatase assay, the reaction conditions will require optimization for each PTPase. Adjusting the temperature, reaction time, and buffer conditions will depend on the PTPase of interest. Vigorous agitation of samples is critical to ensure sufficient mixing of the Sepharose-bound PTPase and its substrate. Lastly, if the phosphatase assay described is not optimal for the particular PTPase of interest, then a phosphatase reaction using p-nitrophenyl phosphate as a substrate can be used as an alternative assay27. 
In live cell imaging experiments, several criteria should be taken into account when preparing a sample. The outlined protocol uses L-15 media based on HEPES buffer, which is not sensitive to CO2 concentration. If the use of a bicarbonate-based media is desired, then HEPES should be supplemented to maintain the pH of the sample or an environmental imaging chamber supplementing CO2 should be used. The protocol recommends applying a layer of mineral oil on top of the sample to prevent evaporation and simplify the addition of rapamycin. Other setups using an environmental imaging chamber or a closed chamber can be used, but the addition of rapamycin could be more challenging. When adding rapamycin to the cells while imaging, ensure that the stage does not shift and the cells are not disturbed. Any additional movements of the sample during the imaging process will obstruct data collection. Illumination intensity and exposure time should be kept low to reduce phototoxicity, especially for long-term imaging. Adequate transfection efficiency of the cells is also critical. A 1:1 ratio of FRB to RapR-Shp2 DNA provides adequate expression, but for new constructs, this ratio will require adjustment. To ensure efficient activation, FRB should be expressed at a higher level than the RapR phosphatase.
A limitation of RapR-based tools is the inability to quickly deactivate. Changing media removes extracellular rapamycin, but deactivation of RapR constructs can take hours due to the very tight binding of rapamycin to the RapR construct. Fast inactivation can be achieved by the addition of an active site inhibitor of the PTPase. However, potential off-target effects of the inhibitor could make interpretation of the results challenging. Furthermore, even in combination with a PTPase inhibitor, the RapR approach cannot be used for cyclical activation/inactivation experiments. Another limitation of the RapR system is the lack of spatial control. RapR constructs are globally expressed and therefore activated everywhere in the cell. One potential solution is the application of caged rapamycin that can be released by near UV light locally in the cell28,29. Further, the RapR tool can be modified to achieve activation of the phosphatase of interest in a specific protein complex or at a specific subcellular location. By attaching a binding partner or a subcellular tag to FRB, RapR-PTPase will be targeted to the specific protein or location in the cell. Lastly, rapamycin is a well-characterized immunosuppressor via mTOR inhibition and can influence cellular signaling, potentially disrupting the signaling of the PTPase of interest. To overcome this concern, non-immunosuppressive analogs of rapamycin (iRap and AP21967) represent a good alternative. Both compounds have been shown to regulate RapR constructs14.

Protein tyrosine phosphatases are a critical family of proteins involved in a plethora of cell signaling events. They have been shown to play a key role in the regulation of cell proliferation, migration, and apoptosis1,2,3. Consequently, the dysregulation of protein tyrosine phosphatases leads to a variety of debilitating diseases and disorders4,5,6,7. Studying the physiological function of tyrosine phosphatases and their role in the development of these pathologies has been historically hindered by a lack of tools needed for probing the intricacies of phosphatase signaling8.
Traditionally, phosphatases are studied using methods that do not have the desired specificity and/or do not provide temporal control of their activity. These critical limitations of available tools make it challenging to dissect specific roles of phosphatases in signaling pathways. Overexpression of constitutively active and dominant negative mutants or downregulation of expression of the phosphatase provide specificity but lack temporal control and often can trigger compensatory mechanisms that will mask the true function of the enzyme.
Pharmacological inhibitors allow for the temporal regulation of phosphatases. However, many phosphatase inhibitors are notoriously nonspecific due to the well-conserved composition of the active site in tyrosine phosphatases9. Additionally, due to design constraints, inhibitors targeting the catalytic site exhibit poor cell membrane permeability10. Another limitation of inhibitors is that they only allow for the examination of the effects of phosphatase inactivation11. Thus, there is a need for tools that enable specific, temporally regulatable activation of phosphatases. These tools will allow researchers to identify the direct effects of phosphatase activation, separating them from multiple parallel signaling cascades often activated by biological stimuli. Importantly, tight temporal control of activity enables the identification of transient events induced by a phosphatase and separates the effects of acute and prolonged phosphatase activity. Combining temporal regulation with mutational analysis will allow for a detailed dissection of specific roles of individual domains of the phosphatase and interrogation of its downstream signaling12.
To address the lack of desired capabilities in the existing tools, the Karginov group has developed the Rapamycin Regulated (RapR) system13,14,15. The RapR system utilizes an engineered switch domain, iFKBP, that allows for allosteric regulation of the protein of interest (POI). The insertion of the iFKBP domain at a position allosterically coupled to the catalytic site of the POI renders it susceptible to regulation by rapamycin. In the absence of rapamycin, iFKBP disrupts the catalytic site due to the intrinsically high structural dynamics of iFKBP and thus inactivates the POI. The addition of rapamycin induces the interaction of iFKBP with the co-expressed protein FRB (Figure 1). This causes stabilization of the switch domain, which consequently restores the structure and function of the POI's catalytic domain. As such, the tool allows for specific and temporally regulatable activation of the POI.
<img alt="Protein activation diagram; Shp2 activation via iFKBP/FRB complex formation; molecular interaction." class="xfigimg" src="/files/ftp_upload/67142/67142fig01.jpg" data-altupdatedat="1788304762000" data-alt="Figure 1"> 
Figure 1: Schematic of the RapR-Shp2 rapamycin-regulated system. RapR allows for allosteric activation of the protein of interest with the addition of rapamycin. This figure was modified from Fauser et al.12. Abbreviations: iFKBP = insertable FKBP12; FRB = FKBP-rapamycin-binding domain; R = rapamycin; Shp2 = Src homology-2 domain-containing protein tyrosine phosphatase. <a href="https://www.jove.com/files/ftp_upload/67142/67142fig01large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
The RapR tool can be applied to different protein families. It can be used to regulate protein kinases as well as phosphatases12,14. This protocol will focus on the application of the RapR tool to control Shp2 phosphatase. Shp2 is a ubiquitously expressed protein tyrosine phosphatase that is involved in signaling processes such as proliferation, migration, immunomodulation, and differentiation1,16,17,18. Dysregulation of Shp2 has been associated with a number of solid cancers, myeloid leukemia, and developmental disorders5,7. However, Shp2 has fallen victim to the same tool shortcomings as described above. To combat these limitations, RapR-Shp2, a specifically and temporally regulatable Shp2 construct, was developed and characterized12.
Prior to the development of RapR-Shp2, it was known that Shp2 was involved in cell migration19,20,21. However, its specific role in the signaling involved in this process was unknown. It was also unknown on what time scale Shp2 regulates the migration of cells and what specific morphodynamic changes it induces at different time points of its activation. Further, it was unclear whether acute and prolonged activation of Shp2 will cause different effects. Using RapR-Shp2, it was found that acute activation of Shp2 induces transient cell spreading, an increase in protrusions, cell polarization, and migration. Specific pathways downstream of Shp2 that regulate distinct morphodynamic changes were also identified12. This protocol provides details for the design and characterization of RapR-Shp2, which can be used to guide the development and application of other RapR phosphatases.

<table><tbody><tr><td>#1.5 Glass Coverslips 25 mm Round</td><td>Warner Instruments</td><td>64-0715</td><td></td></tr><tr><td>1.5 mL Tubes</td><td>USA Scientific</td><td>cc7682-3394</td><td></td></tr><tr><td>2x Laemmli Buffer</td><td></td><td></td><td>For 500 mL: 5.18 g Tris-HCL, 131.5 mL glycerol, 52.5 mL 20% SDS, 0.5 g bromophenol blue, final pH 6.8</td></tr><tr><td>4-20% Mini-PROTEAN TGX Precast Gel</td><td>Biorad</td><td>4561096</td><td></td></tr><tr><td>5x Phusion Plus Buffer</td><td>Thermo Scientific</td><td>F538L</td><td></td></tr><tr><td>A431 Cells</td><td>ATCC</td><td>CRL-1555</td><td></td></tr><tr><td>Agarsose</td><td>GoldBiotech</td><td>A-201</td><td></td></tr><tr><td>Attofluor Cell Chamber</td><td>invitrogen</td><td>A7816</td><td></td></tr><tr><td>Benchmark Fetal Bovine Serum (FBS)</td><td>Gemini Bio-products</td><td>100-106</td><td>Heat Inactivated Triple 0.1 &amp;micro;m sterile-filtered</td></tr><tr><td>Brig 35,30 w/v %</td><td>Acros</td><td>329581000</td><td></td></tr><tr><td>BSA</td><td>GoldBiotech</td><td>A-420</td><td></td></tr><tr><td>CellGeo</td><td>N/A</td><td>N/A</td><td>Published in 10.1083/jcb.201306067</td></tr><tr><td>CellMask Deep Red plasma membrane dye</td><td>invitrogen</td><td>c10046</td><td></td></tr><tr><td>Colony Screen MasterMix</td><td>Genesee</td><td>42-138</td><td></td></tr><tr><td>DH5a competent cells</td><td>NEB</td><td>C2987H</td><td></td></tr><tr><td>DMEM</td><td>Corning</td><td>15-013-CV</td><td></td></tr><tr><td>DMSO</td><td>Thermo Scientific</td><td>F-515</td><td></td></tr><tr><td>DNA Ladder</td><td>GoldBio</td><td>D010-500</td><td></td></tr><tr><td>dNTPs</td><td>NEB</td><td>N04475</td><td></td></tr><tr><td>DpnI Enzyme</td><td>NEB</td><td>R01765</td><td></td></tr><tr><td>DTT</td><td>GoldBio</td><td>DTT10</td><td>DL-Dithiothreitol, Cleland&#039;s Reagents</td></tr><tr><td>EGTA</td><td>Acros</td><td>409910250</td><td></td></tr><tr><td>Fibronectin from bovine plasma</td><td>Sigma</td><td>F1141</td><td></td></tr><tr><td>FuGENE(R) 6 Transfection Reagent</td><td>Promega</td><td>E2692</td><td>transfection reagent</td></tr><tr><td>Gel extraction Kit</td><td>Thermo Scientific</td><td>K0692</td><td>GeneJET Gel Extraction Kit</td></tr><tr><td>Gel Green Nucleic Acid Stain</td><td>GoldBio</td><td>G-740-500</td><td></td></tr><tr><td>Gel Loading Dye Purple 6x</td><td>NEB</td><td>B7024A</td><td></td></tr><tr><td>Glutamax</td><td>Gibco</td><td>35050-061</td><td>GlutaMAX-l (100x) 100 mL</td></tr><tr><td>HEK 293T Cells</td><td>ATCC</td><td>CRL-11268</td><td></td></tr><tr><td>HeLa Cells</td><td>ATCC</td><td>CRM-CCL-2</td><td></td></tr><tr><td>HEPES</td><td>Fischer</td><td>BP310-500</td><td></td></tr><tr><td>ImageJ Processing Software</td><td>N/A</td><td>N/A</td><td></td></tr><tr><td>Igepal CA-630 (NP40)</td><td>Sigma</td><td>I3021</td><td></td></tr><tr><td>Imidazole Buffer</td><td></td><td></td><td>25 mM Imidazole pH 7.2, 2.5 mM EDTA, 50 mM NaCl, 5 mM DTT</td></tr><tr><td>KCl</td><td>Sigma</td><td>P-4504</td><td></td></tr><tr><td>L-15 1x</td><td>Corning</td><td>10-045-CV</td><td></td></tr><tr><td>LB Agar</td><td>Fisher</td><td>BP1425-2</td><td></td></tr><tr><td>Lysis Buffer</td><td></td><td></td><td>20 mM Hepes-KOH, pH 7.8, 50 mM KCl, 1 mM EGTA, 1% NP40</td></tr><tr><td>MATLAB</td><td>MathWorks</td><td>N/A</td><td>R 2022b update was used to run CellGeo functions</td></tr><tr><td>Metamorph Microscopy Automation and Image Analysis Software</td><td>N/A</td><td>N/A</td><td></td></tr><tr><td>MgCl&lt;sub&gt;2&lt;/sub&gt;</td><td>Fisher Chemical</td><td>M33-500</td><td></td></tr><tr><td>Mineral Oil</td><td>Sigma</td><td>M5310</td><td></td></tr><tr><td>MiniPrep Kit</td><td>Gene Choice</td><td>96-308</td><td></td></tr><tr><td>Mini-PROTEAN TGX Precast Gels 12 well</td><td>Bio-Rad</td><td>4561085</td><td></td></tr><tr><td>Molecular Biology Grade Water</td><td>Corning</td><td>46-000-CV</td><td></td></tr><tr><td>Multiband Polychroic Mirror</td><td>Chroma Technology</td><td>89903BS</td><td></td></tr><tr><td>NaCl</td><td>Fisher Chemical</td><td>S271-3</td><td></td></tr><tr><td>Olympus UPlanSAPO 40x objective</td><td>Olympus</td><td>N/A</td><td></td></tr><tr><td>PBS w/o Ca and Mg</td><td>Corning</td><td>21-031-CV</td><td></td></tr><tr><td>PCR Tubes</td><td>labForce</td><td>1149Z65</td><td>0.2 mL 8-Strip Tubes and Caps, Rigid Strip Individually Attached Dome Caps</td></tr><tr><td>Phusion Plus DNA Polymerase</td><td>Thermo Scientific</td><td>F630S</td><td></td></tr><tr><td>Primers</td><td>IDT</td><td></td><td></td></tr><tr><td>Protein-G Sepharose</td><td>Millipore</td><td>16-266</td><td></td></tr><tr><td>PVDF Membranes</td><td>BioRad</td><td>1620219</td><td>Immun-Blot PVDF/Filter Paper Sandwiches</td></tr><tr><td>Rapamycin</td><td>Fisher</td><td>AAJ62473MF</td><td></td></tr><tr><td>0.25% Trypsin, 2.21 mM EDTA, 1x [-] sodium</td><td>Corning</td><td>25-053-CI</td><td></td></tr><tr><td>Tris-Acetate-EDTA (TAE) 50x</td><td>Fischer</td><td>BP1332-1</td><td>for electrophoresis</td></tr><tr><td>Wash Buffer</td><td></td><td></td><td>20 mM Hepes-KOH, pH 7.8, 50 mM KCl, 100 mM NaCl, 1 mM EGTA, 1% NP40</td></tr><tr><td>&amp;beta;-Mercaptoethanol</td><td>Fisher Chemical</td><td>O3446I-100</td><td></td></tr><tr><td>&lt;strong&gt;Antibodies&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Anti-EGFR Antibody</td><td>Cell Signaling</td><td>2232</td><td></td></tr><tr><td>Anti-Erk 1/2 Antibody</td><td>Cell Signaling</td><td>9102</td><td></td></tr><tr><td>Anti-Flag Antibody</td><td>Millipore-Sigma</td><td>F3165</td><td></td></tr><tr><td>Anti-GAPDH Antibody</td><td>invitrogen</td><td>AM4300</td><td></td></tr><tr><td>Anti-GFP Antibody</td><td>Clontech</td><td>632380</td><td></td></tr><tr><td>Anti-mCherry Antibody</td><td>invitrogen</td><td>M11217</td><td></td></tr><tr><td>Anti-paxillin Antibody</td><td>Thermo Fischer</td><td>BDB612405</td><td></td></tr><tr><td>Anti-phospho-EGFR Y992 Antibody</td><td>Cell Signaling</td><td>2235</td><td></td></tr><tr><td>Anti-phospho-Erk 1/2 T202/Y204 Antibody</td><td>Cell Signaling</td><td>9101</td><td></td></tr><tr><td>Anti-phospho-paxillin Y31 Antibody</td><td>Millipore-Sigma</td><td>05-1143</td><td></td></tr><tr><td>Anti-phospho-PLC&amp;gamma; Y783 Antibody</td><td>Cell Signaling</td><td>14008</td><td></td></tr><tr><td>Anti-PLC&amp;gamma; Antibody</td><td>Cell Signaling</td><td>5690</td><td></td></tr></tbody></table>

development and application of rapamycin-regulated tyrosine phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Tyrosine phosphatases are an important family of enzymes that regulate critical physiological functions. They are often dysregulated in human diseases, making them key targets of biological studies. Tools that enable the regulation of phosphatase activity are instrumental in the dissection of their function. Traditional approaches, such as overexpression of constitutively active or dominant negative mutants, or downregulation using siRNA, lack temporal control. Phosphatase inhibitors often have poor specificity, and they only allow researchers to determine what processes are affected by the inhibition of the phosphatase. 
We developed a chemogenetic approach, the Rapamycin-regulated (RapR) system, which allows for allosteric regulation of a phosphatase catalytic domain that enables tight temporal control of phosphatase activation. The RapR system consists of an iFKBP domain inserted into an allosteric site in the phosphatase. The intrinsic structural dynamics of the RapR domain disrupt the catalytic domain, leading to the inactivation of the enzyme. The addition of rapamycin mediates the formation of a complex between iFKBP and a co-expressed FRB protein, which stabilizes iFKBP and restores activity to the phosphatase's catalytic domain. 
This system provides high specificity and tight temporal control of phosphatase activation in living cells. The unique capabilities of this system enable the identification of transient events and interrogation of individual signaling pathways downstream of a phosphatase. This protocol describes guidelines for the development of a RapR-phosphatase, its biochemical characterization, and the analysis of its effects on downstream signaling and regulation of cell morphodynamics. It also provides a detailed description of a protein engineering strategy, in vitro assays analyzing phosphatase activity, and live cell imaging experiments identifying changes in cell morphology.

Figure 4 demonstrates results that can be expected from the paxillin-based phosphatase activity assay. In this experiment, constitutively active and dominant negative Shp2 phosphatase activity was compared to that of active and inactive RapR-Shp2 using phospho-paxillin as the readout. The Shp2 constructs were immunoprecipitated and subjected to the activity assay as described in the protocol. The phospho-paxillin readouts for constitutively active Shp2 and active RapR-Shp2 were similar, indicating that the active RapR-Shp2 had not been affected negatively by the introduction of the RapR domain and it retained full activity once activated. Dominant negative Shp2 and inactive RapR-Shp2 were also similar, indicating that the RapR-Shp2 construct does not have activity when inactive. This indicates the successful design of a RapR-phosphatase. The phospho-substrate used for this assay may differ based on the phosphatase of interest.
Figure 5, similar to Figure 4, compares constitutively active, dominant negative, and active and inactive RapR-Shp2. This experiment was conducted without immunoprecipitation of the constructs. Instead, it was designed to characterize the downstream signaling effects of the RapR-Shp2 construct within cells. Here, the Shp2 constructs were expressed in HEK293T cells. Downstream effector ERK1/2 was shown to increase in phosphorylation in response to RapR-Shp2 activation, just as in the constitutively active sample. The inactive RapR-Shp2 did not induce this change. This indicates that downstream signaling of Shp2 is preserved with the incorporation of the RapR-domain. Similarly, known phospho-substrates EGFR and PLCγ were dephosphorylated in response to RapR-Shp2 activation in A431 cells.
Finally, Figure 6 presents the results of RapR-Shp2 activation on the morphodynamics of HeLa cells. Once RapR-Shp2 was activated, the cells showed an increase in protrusive activity as well as cell area. This indicates that RapR-Shp2 activation is sufficient to induce morphodynamic changes in HeLa cells and may allow researchers to probe specific downstream signaling pathways responsible for this effect.
<img alt="Western blot showing protein expression with Rapamycin treatment; Paxillin, Flag-Shp2 bands." class="xfigimg" src="/files/ftp_upload/67142/67142fig04.jpg" data-altupdatedat="1788304762000" data-alt="Figure 4"> 
Figure 4: Results from the paxillin-based activity assay: Constitutively active, dominant negative, and RapR-Shp2 were immunoprecipitated and subject to the activity assay using the outlined protocol. The levels of pY31 paxillin in both CA and RapR-Shp2 were similar, indicating that the RapR-Shp2 construct had similar activity compared to CA Shp2 once activated. The non-activated RapR-Shp2 sample had no activity, similar to the DN sample, indicating that it was not "leaky". This figure was modified from Fauser et al.12. Abbreviations: RapR = Rapamycin-regulated; Shp2 = Src homology-2 domain-containing protein tyrosine phosphatase; DN = dominant negative; CA = constitutively active; FRB = FKBP-rapamycin-binding domain. <a href="https://www.jove.com/files/ftp_upload/67142/67142fig04large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Western blot analysis, phospho-ERK signaling, rapamycin effects, protein expression comparison." class="xfigimg" src="/files/ftp_upload/67142/67142fig05.jpg" data-altupdatedat="1788304762000" data-alt="Figure 5"> 
Figure 5: Results from the whole-cell lysate assay: Constitutively active, dominant negative, and RapR-Shp2 were expressed in HEK293T cells and the whole-cell lysate protocol was completed. When inactive, RapR-Shp2 did not activate ERK1/2 by phosphorylation, similar to the DN Shp2 sample. This indicates that RapR-Shp2 does not have activity when inactive. Once activated, the level of ERK1/2 phosphorylation was similar to that of the CA Shp2 sample, indicating successful activation and downstream signaling of Shp2. Similarly, A431 cells expressing RapR-Shp2 showed decreases in phosphorylation of both EGFR and PLCγ, both known substrates of Shp2. This figure was modified from Fauser et al.12. Abbreviations: RapR = Rapamycin-regulated; Shp2 = Src homology-2 domain-containing protein tyrosine phosphatase; DN = dominant negative; CA = constitutively active; ERK = extracellular signal-regulated kinase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; EGFR = epidermal growth factor receptor; PLCγ = phospholipase C gamma; FRB = FKBP-rapamycin-binding domain. <a href="https://www.jove.com/files/ftp_upload/67142/67142fig05large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Cell area change analysis; graphs show RapR-Shp2 effects, normalized cell area, protrusive activity." class="xfigimg" src="/files/ftp_upload/67142/67142fig06.jpg" data-altupdatedat="1788304762000" data-alt="Figure 6"> 
Figure 6: Cell area and protrusive activity data analysis based on live imaging: HeLa cells were transfected with RapR-Shp2 and subjected to the outlined live imaging protocol. Data were analyzed as outlined in the data analysis protocol. Once activated (indicated by the vertical grey line), HeLa cells showed increases in both cell protrusive activity as well as cell area. In the negative samples that were only expressing FRB, this activity was not present. This indicates that RapR-Shp2 activation induces fast morphodynamic changes within HeLa cells and encourages cell spreading and protrusion. This figure was modified from Fauser et al.12. <a href="https://www.jove.com/files/ftp_upload/67142/67142fig06large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

This protocol describes the design, creation, and application of rapamycin-regulated phosphatases. This method provides high specificity and tight temporal control of phosphatase activation in living cells.

Tyrosine phosphatases are an important family of enzymes that regulate critical physiological functions. They are often dysregulated in human diseases, ...

development-application-rapamycin-regulated-tyrosine

Research

JoVE Journal

Biology

A method for spatio-temporal control of small GTPase activity by light is described. This method is based on rapamycin-induced FKBP-FRB heterodimerization and photo-caging systems. Optimization of light-irradiation enables the spatio-temporally controlled activation of small GTPases at the subcellular level.

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Here, we present a protocol for the isolation of healthy and functional primary mouse hepatocytes. Instructions for detecting hepatic nascent protein synthesis by non-radioactive labeling substrate were provided to help understand the mechanisms underlying protein synthesis in the context of energy-metabolism homeostasis in the liver.

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Here, we present a protocol for co-immunoprecipitation and an on-bead enzymatic activity assay to simultaneously study the contribution of specific protein domains of plasma membrane receptors to both enzyme recruitment and enzyme activity.

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

In this study, we enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used mTOR-rapamycin interaction as an exemplary case.

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

In this study, we describe a detailed procedure of TNBS-mediated intestinal fibrosis, which exhibits comparable pathophysiology to Crohn's fibrosis. We also discuss this approach in light of rapamycin facilitated inhibitory effects on intestinal fibrosis.

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

The ability to assess target engagement by candidate inhibitors in intact cells is crucial for drug discovery. This protocol describes a 384 well format cellular thermal shift assay that reliably detects cellular target engagement of inhibitors targeting either wild-type SHP2 or its oncogenic variants.

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Jeffrey D. Rothstein speaks about the pathology and mechanisms underlying amyotrophic lateral sclerosis or ALS, advances in ALS research, and current strategies towards the development of therapies.

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

This article describes a novel protocol and reagent set designed for sensitive measurement of neurotoxic effects of compounds and treatments on co-cultures of neurons and astrocytes using high content analysis. Results demonstrate that high content analysis represents an exciting novel technology for neurotoxicity assessment.

A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity

Mammary tumor cells expressing luciferase are implanted subcutaneously in mice and visualized using optical imaging to monitor tumor growth and development non-invasively in a longitudinal study.

In vivo Bioluminescent Imaging of Mammary Tumors Using IVIS Spectrum

This protocol demonstrates how to maintain healthy, undifferentiated human embryonic stem (ES) cells.

Culture and Maintenance of Human Embryonic Stem Cells  

Learn to develop rapamycin-regulated tyrosine phosphatases for temporal control of SHIP-2 activity in HEK-293T cells. This method reveals specific effects on cell spreading and migration.

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Explore More Videos